|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Nicotine | CAS 54-11-5 | ||
| C5H4NC4H7NCH3 | RTECS QS5250000 | ||
|
Synonyms & Trade Names 3-(1-Methyl-2-pyrrolidyl)pyridine |
DOT ID & Guide 1654 151 |
||
|
Exposure Limits |
NIOSH REL: TWA 0.5 mg/m3 [skin] | ||
| OSHA PEL: TWA 0.5 mg/m3 [skin] | |||
| IDLH 5 mg/m3 | Conversion | ||
|
Physical Description Pale-yellow to dark-brown liquid with a fish-like odor when warm. [insecticide] |
|||
|
MW: 162.2 |
BP: 482°F (Decomposes) |
FRZ: -110°F |
Sol: Miscible |
|
VP: 0.08 mmHg |
IP: 8.01 eV |
|
Sp.Gr: 1.01 |
|
Fl.P: 203°F |
UEL: 4.0% |
LEL: 0.7% |
|
| Class IIIB Combustible Liquid: Fl.P. at or above 200�F. | |||
|
Incompatibilities & Reactivities Strong oxidizers, strong acids |
|||
|
Measurement Methods NIOSH 2544, 2551 |
|
Personal Protection & Sanitation Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated Remove: When wet or contaminated Change: No recommendation Provide: Eyewash, Quick drench |
First Aid (See procedures) Eye: Irrigate immediately Skin: Water flush immediately Breathing: Respiratory support Swallow: Medical attention immediately |
|
Respirator Recommendations
NIOSH/OSHA Up to 5 mg/m3: (APF = 10) Any supplied-air respirator/(APF = 50) Any self-contained breathing apparatus with a full facepiece Emergency or planned entry into unknown concentrations or IDLH conditions: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode/(APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister/Any appropriate escape-type, self-contained breathing apparatus |
|
| Exposure Routes inhalation, skin absorption, ingestion, skin and/or eye contact | |
| Symptoms Nausea, salivation, abdominal pain, vomiting, diarrhea; headache, dizziness, hearing, visual disturbance; confusion, lassitude (weakness, exhaustion), incoordination; cardiac arrhythmias; convulsions, dyspnea (breathing difficulty); in animals: teratogenic effects | |
|
Target Organs
central nervous system, cardiovascular system, lungs, gastrointestinal tract, reproductive system |
|
| See also: INTRODUCTION |